The advent of biosimilars for the treatment of diabetes: current status and future directions

Acta Diabetologica

Volumn 52, Issue 3, 2015, Pages 423-431

  Polimeni, Giovanni ^a   Trifirò, Gianluca ^a   Ingrasciotta, Ylenia ^a   Caputi, Achille P ^a  

^a UNIVERSITY OF MESSINA   (Italy)

Author keywords

Biosimilar; Insulin; Pharmacovigilance; Substitution

Indexed keywords

BIOSIMILAR AGENT; HUMAN INSULIN; INSULIN; INSULIN DERIVATIVE; ISOPHANE INSULIN; RECOMBINANT HUMAN INSULIN; SHORT ACTING INSULIN;

ARTICLE; DIABETES MELLITUS; DRUG CONTROL; DRUG EFFICACY; DRUG MANUFACTURE; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; GOOD MANUFACTURING PRACTICE; HUMAN; HYPOGLYCEMIA; IMMUNOGENICITY; INSULIN DEPENDENT DIABETES MELLITUS; NEEDLE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRACTICE GUIDELINE; PRIORITY JOURNAL; SINGLE DRUG DOSE; SYRINGE; ANALOGS AND DERIVATIVES; ANIMAL; TRENDS;

ANIMALS; BIOSIMILAR PHARMACEUTICALS; DIABETES MELLITUS; DRUG THERAPY; HUMANS; INSULIN;

EID: 84930092437     PISSN: 09405429     EISSN: 14325233     Source Type: Journal    
DOI: 10.1007/s00592-015-0771-7     Document Type: Article

References (46)

1. US Food and Drug Administration: guidance for industry: quality considerations in demonstrating biosimilarity to a reference protein product. Rockville, Md., Food and Drug Administration, 2012. http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm291134.pdf. Accessed 15 Feb 2015
2. CHMP: guideline on similar biological medicinal products. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2013/05/WC500142978.pdf. Accessed 15 Feb 2015
3. Committee for Medicinal Products for Human Use. Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: non-clinical and clinical issues. London: EMA, 2014. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2015/01/WC500180219.pdf. Accessed 15 Feb 2015
4. Rotenstein LS, Ran N, Shivers JP, Yarchoan M, Close KL (2012) Opportunities and Challenges for Biosimilars: what’s on the horizon in the global insulin market? Clin Diabetes 30:138–150
5. European Medicines Agency. Pending EC Decision. http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/002835/smops/Positive/human_smop_000706.jsp&mid=WC0b01ac058001d127. Accessed 15 Feb 2015
6. Emerton DA (2013) Profitability in the biosimilars market: can you translate scientific excellence into a healthy commercial return? BioProcess Int 11(6–14):23
7. Minocha M, Gobburu J (2014) Drug development and potential regulatory paths for insulin biosimilars. J Diabetes Sci Technol 8:14–19
8. Genazzani AA, Biggio G, Caputi AP et al (2007) Biosimilar drugs: concerns and opportunities. Bio Drugs 21:351–356
9. Greene JA, Riggs KR (2015) Why is there no generic insulin? Historical origins of a modern problem. N Engl J Med 372:1171–1175
10. Directive 2001/83/CE, modified by the Directive 2003/63/CE and by the Directive 2004/27/CE. http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/document_listing/document_listing_000349.jsp&mid=WC0b01ac05805083eblara. Accessed 15 Feb 2015
11. Committee for Medicinal Products for Human Use. Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: quality issues (revision 1). London: EMA, 2012. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2012/05/WC500127960.pdf. Accessed 15 Feb 2015
12. Schellekens H (2002) Bioequivalence and the immunogenicity of biopharmaceuticals. Nat Rev Drug Discov 1:457–462
13. Jahn EM, Schneider CK (2009) How to systematically evaluate immunogenicity of therapeutic proteins—regulatory considerations. New Biotechnol 25:280–286
14. Biologics Price Competition and Innovation Act of 2009 in the Patient Protection and Affordable Care Act (Public Law 111–148). Washington, D.C., 2010. http://www.gpo.gov/fdsys/pkg/PLAW-111publ148/content-detail.html. Accessed 15 Feb 2015
15. Committee for Medicinal Products for Human Use. Guideline on non-clinical and clinical development of similar biological medicinal products containing recombinant human insulin and insulin analogues. London: EMA, 2012. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2012/12/WC500136392.pdf. Accessed 15 Feb 2015
16. Food and Drug Administration. Diabetes mellitus: developing drugs and therapeutic biologics for treatment and prevention. 2008. http://www.fda.gov/downloads/Drugs/Guidances/ucm071624.pdf. Accessed 15 Feb 2015
17. Kozlowski S, Woodcock J, Midthun K, Sherman RB (2011) Developing the nation’s biosimilars program. N Engl J Med 365:385–388
18. Schellekens H (2004) Biosimilar epoetins: how similar are they? Eur J Hosp Pharm 3:243–247
19. Kuhlmann M, Marre M (2010) Lessons learned from biosimilar epoetins and insulins. Br J Diabetes Vasc Dis 10:90–97
20. Kuhlmann M, Covic A (2006) The protein science of biosimilars. Nephrol Dial Transplant 21(Suppl 5):v4–v8
21. Schellekens H (2005) Follow-on biologics: challenges of the ‘‘next generation’’. Nephrol Dial Transplant 20:iv31–iv36
22. Fineberg SE, Kawabata TT, Finco-Kent D, Fountaine RJ, Finch GL, Krasner AS (2007) Immunological responses to exogenous insulin. Endocr Rev 28:625–652
23. European Medicines Agency. Pre-authorisation evaluation of medicines for human use. Withdrawal Assessment Report for Insulin Human Rapid Marvel. 21 February 2008. London: EMEA, 2008. Document reference EMEA/CHMP/317778/2007. www.emea.europa.eu/humandocs/PDFs/EPAR/insulinhumanrapidmarvel/31777807en.pdf. Accessed 15 Feb 2015
24. European Medicines Agency. Pre-authorisation evaluation of medicines for human use. Withdrawal Assessment Report for Insulin Human Long Marvel. 21 February 2008. London: EMEA, 2008. Document reference EMEA/CHMP/70349/2008. www.emea.europa.eu/humandocs/PDFs/EPAR/insulinhumanrapidmarvel/7034908en.pdf. Accessed 15 Feb 2015
25. European Medicines Agency. Pre-authorisation evaluation of medicines for human use. Withdrawal Assessment Report for Insulin Human 30/70 Mixed Marvel. 21 February 2008. London: EMEA, 2008. Document reference EMEA/CHMP/70179/2008. www.emea.europa.eu/humandocs/PDFs/EPAR/insulinhumanrapidmarvel/701790en.pdf. Accessed 15 Feb 2015
26. European Medicines Agency. Press release: Marvel LifeSciences Ltd withdraws its marketing authorisation applications for Insulin Human Rapid Marvel, Insulin Human Long Marvel and Insulin Human 30/70 Mix Marvel. 16 January 2008. London: EMEA, 2008. EMEA/2435/2008
27. EMA Procedural advice for users of the centralized procedure for similar biological medicinal products applications. March 2013. EMA/940451/2011. Committee for Human Medicinal Products (CHMP) http://www.ema.europa.eu/docs/en_GB/document_library/Regulatory_and_procedural_guideline/2012/04/WC500125166.pdf. Accessed 15 Feb 2015
28. Hasani-Ranjbar S, Fazlollahi MR, Mehri A, Larijani B (2012) Allergy to human insulin and specific immunotherapy with glargine; case report with review of literature. Acta Diabetol 49:69–73
29. Schellekens H (2008) The first biosimilar epoetin: but how similar is it? Clin J Am Soc Nephrol 3:174–178
30. Hermeling S, Crommelin DJ, Schellekens H, Jiskoot W (2004) Structure-immunogenicity relationships of therapeutic proteins. Pharm Res 21:897–903
31. Kessler M, Goldsmith D, Schellekens H (2006) Immunogenicity of biopharmaceuticals. Nephrol Dial Transplant 21:v9–v12
32. Yanai H, Adachi H, Hamasaki H (2011) Diabetic ketosis caused by the insulin analog aspart-induced anti-insulin antibody: successful treatment with the newest insulin analog glulisine. Diabetes Care 34:e108
33. Bartelds GM, Wijbrandts CA, Nurmohamed MT, Stapel S, Lems WF, Aarden L, Dijkmans BA, Tak PP, Wolbink GJ (2010) Anti-infliximab and anti-adalimumab antibodies in relation to response to adalimumab in infliximab switchers and anti-tumour necrosis factor naive patients: a cohort study. Ann Rheum Dis 69:817–821
34. Zuniga L, Calvo B (2010) Biosimilars: pharmacovigilance and risk management. Pharmacoepidemiol Drug Saf 19:661–669
35. Regulation (EU) No. 1235/2010 of the European Parliament and of the Council of 15 December 2010 amending, as regards pharmacovigilance of medicinal products for human use, Regulation (EC) No. 726/2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency, and Regulation (EC) No. 1394/2007 on advanced therapy medicinal products. Official Journal of the European Union L 348/1, 31/12/2010
36. Directive 2010/84/EU of the European Parliament and of the Council of 15 December 2010 amending, as regards pharmacovigilance, Directive 2001/83/EC on the Community code relating to medicinal products for human use. Official Journal of the European Union L 348/74, 31/12/2010
37. Amendments to the pharmacovigilance legislation: new notification requirements for marketing-authorisation holders. 2013. http://www.ema.europa.eu. Accessed 15 Feb 2015
38. Pharmacovigilance Focus. Biosimilar medicines and safety: new challenges for pharmacovigilance. WHO Drug Inf. 2009; 23:87–94. http://www.who.int/druginformation. Accessed 15 Feb 2015
39. Vermeer NS, Spierings I, Mantel-Teeuwisse AK, Straus SM, Giezen TJ, Leufkens HG, Egberts TC, De Bruin ML (2015) Traceability of biologicals: present challenges in pharmacovigilance. Expert Opin Drug Saf. 14:63–72
40. Walsh G (2005) Therapeutic insulins and their large-scale manufacture. Appl Microbiol Biotechnol 67:151–159
41. Joshi SR, Parikh RM, Das AK (2007) Insulin: history, biochemistry, physiology and pharmacology. J Assoc Physicians India 55(suppl):19–25
42. Vigneri R, Squatrito S, Sciacca L (2010) Insulin and its analogs: actions via insulin and IGF receptors. Acta Diabetol 47:271–278
43. Selam J-L (2010) Evolution of diabetes insulin delivery devices. J Diabetes Sci Technol 4:505–513
44. European Medicines Agency. Guideline on the suitability of the graduation of delivery devices for liquid dosage forms. Doc Ref EMEA/CHMP/QWP/178621/2004. London: EMA, 2005. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003660.pdf. Accessed 15 Feb 2015
45. International Organization for Standardization. Pen-injectors for medical use. Part 1: pen-injectors. Requirements and test methods (ISO 11608–1:2000). Geneva: ISO, 2000
46. US Food and Drug Administration: guidance for industry regarding implementation of the guidance for industry biosimilars: questions and answers. Rockville, Md., US Food and Drug Administration, 2012